Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1993 Dec;70(6):499–502. doi: 10.1136/hrt.70.6.499

Anthracyclines and the heart.

W Rhoden 1, P Hasleton 1, N Brooks 1
PMCID: PMC1025378  PMID: 8280512

Full text

PDF
499

Images in this article

500Image
on p.500

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aricò M., Pedroni E., Nespoli L., Viganò M., Porta F., Burgio G. R. Long term survival after heart transplantation for doxorubicin induced cardiomyopathy. Arch Dis Child. 1991 Aug;66(8):985–986. doi: 10.1136/adc.66.8.985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Armitage J. M., Kormos R. L., Griffith B. P., Fricker F. J., Hardesty R. L. Heart transplantation in patients with malignant disease. J Heart Transplant. 1990 Nov-Dec;9(6):627–630. [PubMed] [Google Scholar]
  3. Arnold A. Z., Razavi M. Right heart failure after chemotherapy. Cleve Clin J Med. 1991 Jul-Aug;58(4):357–360. doi: 10.3949/ccjm.58.4.357. [DOI] [PubMed] [Google Scholar]
  4. Blum R. H., Carter S. K. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med. 1974 Feb;80(2):249–259. doi: 10.7326/0003-4819-80-2-249. [DOI] [PubMed] [Google Scholar]
  5. Bristow M. R., Mason J. W., Billingham M. E., Daniels J. R. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981 Oct;102(4):709–718. doi: 10.1016/0002-8703(81)90096-x. [DOI] [PubMed] [Google Scholar]
  6. Bu'Lock F. A., Gabriel H. M., Oakhill A., Mott M. G., Martin R. P. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J. 1993 Aug;70(2):185–188. doi: 10.1136/hrt.70.2.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carrió I., Estorch M., Berná L., Germá J. R., Alonso C., Ojeda B., de Andrés L., Lopez-Pousa A., Martinez-Duncker C., Torres G. Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med. 1991;18(10):806–812. doi: 10.1007/BF00175059. [DOI] [PubMed] [Google Scholar]
  8. Carrió I., Estorch M., Berná L., Germá J. R., Alonso C., Ojeda B., de Andrés L., Lopez-Pousa A., Martinez-Duncker C., Torres G. Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med. 1991;18(10):806–812. doi: 10.1007/BF00175059. [DOI] [PubMed] [Google Scholar]
  9. Cittadini A., Fazio S., D'Ascia C., Basso A., Bazzicalupo L., Picardi G., Saccà L. Subclinical cardiotoxicity by doxorubicin: a pulsed Doppler echocardiographic study. Eur Heart J. 1991 Sep;12(9):1000–1005. [PubMed] [Google Scholar]
  10. Dey H. M., Kassamali H. Radionuclide evaluation of doxorubicin cardiotoxicity: the need for cautious interpretation. Clin Nucl Med. 1988 Aug;13(8):565–568. doi: 10.1097/00003072-198808000-00002. [DOI] [PubMed] [Google Scholar]
  11. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992 Sep 3;327(10):685–691. doi: 10.1056/NEJM199209033271003. [DOI] [PubMed] [Google Scholar]
  12. Freter C. E., Lee T. C., Billingham M. E., Chak L., Bristow M. R. Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review. Am J Med. 1986 Mar;80(3):483–485. doi: 10.1016/0002-9343(86)90724-2. [DOI] [PubMed] [Google Scholar]
  13. Fu L. X., Waagstein F., Hjalmarson A. A new insight into adriamycin-induced cardiotoxicity. Int J Cardiol. 1990 Oct;29(1):15–20. doi: 10.1016/0167-5273(90)90267-9. [DOI] [PubMed] [Google Scholar]
  14. Galaris D., Georgellis A., Rydström J. Toxic effects of daunorubicin on isolated and cultured heart cells from neonatal rats. Biochem Pharmacol. 1985 Apr 1;34(7):989–995. doi: 10.1016/0006-2952(85)90601-x. [DOI] [PubMed] [Google Scholar]
  15. Goorin A. M., Chauvenet A. R., Perez-Atayde A. R., Cruz J., McKone R., Lipshultz S. E. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr. 1990 Jan;116(1):144–147. doi: 10.1016/s0022-3476(05)81668-3. [DOI] [PubMed] [Google Scholar]
  16. Gottlieb S. L., Edmiston W. A., Jr, Haywood L. J. Late, late doxorubicin cardiotoxicity. Chest. 1980 Dec;78(6):880–882. doi: 10.1378/chest.78.6.880. [DOI] [PubMed] [Google Scholar]
  17. Green M. D., Alderton P., Gross J., Muggia F. M., Speyer J. L. Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529). Pharmacol Ther. 1990;48(1):61–69. doi: 10.1016/0163-7258(90)90018-w. [DOI] [PubMed] [Google Scholar]
  18. Hitchcock-Bryan S., Gelber R., Cassady J. R., Sallan S. E. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14(4):211–215. doi: 10.1002/mpo.2950140405. [DOI] [PubMed] [Google Scholar]
  19. Hortobagyi G. N., Buzdar A. U., Marcus C. E., Smith T. L. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;(1):105–109. [PubMed] [Google Scholar]
  20. Hortobagyi G. N., Frye D., Buzdar A. U., Ewer M. S., Fraschini G., Hug V., Ames F., Montague E., Carrasco C. H., Mackay B. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 1989 Jan 1;63(1):37–45. doi: 10.1002/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  21. Hrushesky W. J., Fader D. J., Berestka J. S., Sommer M., Hayes J., Cope F. O. Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. Circulation. 1991 Aug;84(2):697–707. doi: 10.1161/01.cir.84.2.697. [DOI] [PubMed] [Google Scholar]
  22. Hrushesky W. J., Fader D. J., Berestka J. S., Sommer M., Hayes J., Cope F. O. Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. Circulation. 1991 Aug;84(2):697–707. doi: 10.1161/01.cir.84.2.697. [DOI] [PubMed] [Google Scholar]
  23. Ito H., Miller S. C., Billingham M. E., Akimoto H., Torti S. V., Wade R., Gahlmann R., Lyons G., Kedes L., Torti F. M. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4275–4279. doi: 10.1073/pnas.87.11.4275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ito H., Miller S. C., Billingham M. E., Akimoto H., Torti S. V., Wade R., Gahlmann R., Lyons G., Kedes L., Torti F. M. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4275–4279. doi: 10.1073/pnas.87.11.4275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Jain K. K., Casper E. S., Geller N. L., Hakes T. B., Kaufman R. J., Currie V., Schwartz W., Cassidy C., Petroni G. R., Young C. W. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985 Jun;3(6):818–826. doi: 10.1200/JCO.1985.3.6.818. [DOI] [PubMed] [Google Scholar]
  26. Lefrak E. A., Pitha J., Rosenheim S., Gottlieb J. A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 Aug;32(2):302–314. doi: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  27. Lipshultz S. E., Colan S. D., Gelber R. D., Perez-Atayde A. R., Sallan S. E., Sanders S. P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991 Mar 21;324(12):808–815. doi: 10.1056/NEJM199103213241205. [DOI] [PubMed] [Google Scholar]
  28. Lipshultz S. E., Colan S. D., Gelber R. D., Perez-Atayde A. R., Sallan S. E., Sanders S. P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991 Mar 21;324(12):808–815. doi: 10.1056/NEJM199103213241205. [DOI] [PubMed] [Google Scholar]
  29. Marchandise B., Schroeder E., Bosly A., Doyen C., Weynants P., Kremer R., Pouleur H. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989 Jul;118(1):92–98. doi: 10.1016/0002-8703(89)90077-x. [DOI] [PubMed] [Google Scholar]
  30. Marchandise B., Schroeder E., Bosly A., Doyen C., Weynants P., Kremer R., Pouleur H. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989 Jul;118(1):92–98. doi: 10.1016/0002-8703(89)90077-x. [DOI] [PubMed] [Google Scholar]
  31. Mitrius J. C., Vogel S. M. Doxorubicin-induced automaticity in cultured chick heart cell aggregates. Cancer Res. 1990 Jul 15;50(14):4209–4215. [PubMed] [Google Scholar]
  32. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  33. Schmitt-Gräff A., Scheulen M. E. Prevention of adriamycin cardiotoxicity by niacin, isocitrate or N-acetyl-cysteine in mice. A morphological study. Pathol Res Pract. 1986 May;181(2):168–174. doi: 10.1016/S0344-0338(86)80006-1. [DOI] [PubMed] [Google Scholar]
  34. Shapira J., Gotfried M., Lishner M., Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer. 1990 Feb 15;65(4):870–873. doi: 10.1002/1097-0142(19900215)65:4<870::aid-cncr2820650407>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  35. Sperber A. D., Cantor A. A., Biran H., Keynan A. Selective right ventricular dysfunction following doxorubicin therapy. Isr J Med Sci. 1987 Aug;23(8):896–899. [PubMed] [Google Scholar]
  36. Sperber A. D., Cantor A. A., Biran H., Keynan A. Selective right ventricular dysfunction following doxorubicin therapy. Isr J Med Sci. 1987 Aug;23(8):896–899. [PubMed] [Google Scholar]
  37. Speyer J. L., Green M. D., Dubin N., Blum R. H., Wernz J. C., Roses D., Sanger J., Muggia F. M. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med. 1985 Apr;78(4):555–563. doi: 10.1016/0002-9343(85)90395-x. [DOI] [PubMed] [Google Scholar]
  38. Speyer J. L., Green M. D., Kramer E., Rey M., Sanger J., Ward C., Dubin N., Ferrans V., Stecy P., Zeleniuch-Jacquotte A. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988 Sep 22;319(12):745–752. doi: 10.1056/NEJM198809223191203. [DOI] [PubMed] [Google Scholar]
  39. Steinberg J. S., Cohen A. J., Wasserman A. G., Cohen P., Ross A. M. Acute arrhythmogenicity of doxorubicin administration. Cancer. 1987 Sep 15;60(6):1213–1218. doi: 10.1002/1097-0142(19870915)60:6<1213::aid-cncr2820600609>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  40. Steinberg J. S., Wasserman A. G. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity. Clin Ther. 1985;7(6):660–667. [PubMed] [Google Scholar]
  41. Steinherz L. J., Graham T., Hurwitz R., Sondheimer H. M., Schwartz R. G., Shaffer E. M., Sandor G., Benson L., Williams R. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992 May;89(5 Pt 1):942–949. [PubMed] [Google Scholar]
  42. Steinherz L. J., Steinherz P. G., Tan C. T., Heller G., Murphy M. L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991 Sep 25;266(12):1672–1677. [PubMed] [Google Scholar]
  43. Steinherz L., Steinherz P. Delayed cardiac toxicity from anthracycline therapy. Pediatrician. 1991;18(1):49–52. [PubMed] [Google Scholar]
  44. Stoddard M. F., Seeger J., Liddell N. E., Hadley T. J., Sullivan D. M., Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992 Jul;20(1):62–69. doi: 10.1016/0735-1097(92)90138-d. [DOI] [PubMed] [Google Scholar]
  45. Stoddard M. F., Seeger J., Liddell N. E., Hadley T. J., Sullivan D. M., Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992 Jul;20(1):62–69. doi: 10.1016/0735-1097(92)90138-d. [DOI] [PubMed] [Google Scholar]
  46. Sunnenberg T. D., Kramer B. Long-term effects of cancer chemotherapy. Compr Ther. 1985 Sep;11(9):58–67. [PubMed] [Google Scholar]
  47. Valdés Olmos R. A., ten Bokkel Huinink W. W., Greve J. C., Hoefnagel C. A. I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med. 1992 Mar;17(3):163–167. doi: 10.1097/00003072-199203000-00001. [DOI] [PubMed] [Google Scholar]
  48. Villani F., Comazzi R., Genitoni V., Lacaita G., Guindani A., Crippa F., Monti E., Piccinini F., Rozza A., Lanza E. Preliminary evaluation of myocardial toxicity of 4'-deoxydoxorubicin: experimental and clinical results. Drugs Exp Clin Res. 1985;11(3):223–231. [PubMed] [Google Scholar]
  49. Villani F., Comazzi R., Lacaita G., Guindani A., Genitoni V., Volonterio A., Brambilla M. C. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med Oncol Tumor Pharmacother. 1985;2(2):93–97. doi: 10.1007/BF02934854. [DOI] [PubMed] [Google Scholar]
  50. Viniegra M., Marchetti M., Losso M., Navigante A., Litovska S., Senderowicz A., Borghi L., Lebron J., Pujato D., Marrero H. Cardiovascular autonomic function in anthracycline-treated breast cancer patients. Cancer Chemother Pharmacol. 1990;26(3):227–231. doi: 10.1007/BF02897205. [DOI] [PubMed] [Google Scholar]
  51. Von Hoff D. D., Rozencweig M., Layard M., Slavik M., Muggia F. M. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977 Feb;62(2):200–208. doi: 10.1016/0002-9343(77)90315-1. [DOI] [PubMed] [Google Scholar]
  52. Von Hoff D. D., Rozencweig M., Layard M., Slavik M., Muggia F. M. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977 Feb;62(2):200–208. doi: 10.1016/0002-9343(77)90315-1. [DOI] [PubMed] [Google Scholar]
  53. Von Hoff D. D., Rozencweig M., Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol. 1982 Mar;9(1):23–33. [PubMed] [Google Scholar]
  54. Watts R. G. Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: evidence for enhanced toxicity with multiagent chemotherapy. Am J Hematol. 1991 Mar;36(3):217–218. doi: 10.1002/ajh.2830360314. [DOI] [PubMed] [Google Scholar]
  55. Weiss A. J., Metter G. E., Fletcher W. S., Wilson W. L., Grage T. B., Ramirez G. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep. 1976 Jul;60(7):813–822. [PubMed] [Google Scholar]
  56. Wortman J. E., Lucas V. S., Jr, Schuster E., Thiele D., Logue G. L. Sudden death during doxorubicin administration. Cancer. 1979 Nov;44(5):1588–1591. doi: 10.1002/1097-0142(197911)44:5<1588::aid-cncr2820440508>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  57. Yamada T., Matsumori A., Tamaki N., Morishima S., Watanabe Y., Yonekura Y., Endo K., Konishi J., Kawai C. Detection of adriamycin cardiotoxicity with indium-111 labeled antimyosin monoclonal antibody imaging. Jpn Circ J. 1991 Apr;55(4):377–383. doi: 10.1253/jcj.55.377. [DOI] [PubMed] [Google Scholar]
  58. Yeung S. T., Yoong C., Spink J., Galbraith A., Smith P. J. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet. 1991 Apr 6;337(8745):816–818. doi: 10.1016/0140-6736(91)92516-5. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES